Product Description
CANMAb(TM) 440 mg Injection which contains trastuzumab used for the treatment of HER2-positive metastatic breast cancer in India. CANMAb(TM), developed jointly by Biocon Pharma and Mylan under a global partnership, is being introduced for the benefit of patients in India. Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb(TM) will offer a high quality, more affordable option to breast cancer patients in India.